Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
News and updates for Precision BioSciences, Inc. (Nasdaq: DTIL) center on its progress as a clinical stage gene editing company using the ARCUS platform to develop in vivo therapies for serious genetic and infectious diseases. Company announcements frequently highlight developments in its pipeline, clinical trial milestones, scientific publications, and capital markets activity.
A major focus of Precision’s news flow is PBGENE-HBV, the company’s wholly owned in vivo gene editing program for chronic hepatitis B. Updates include data from the global ELIMINATE-B trial, covering safety, dose-dependent antiviral activity, reductions in hepatitis B surface antigen (HBsAg), and biopsy evidence of ARCUS-mediated viral DNA editing. Press releases also describe regulatory designations such as Breakthrough Therapy status and the expansion of clinical trial sites across multiple countries.
Another recurring theme is PBGENE-DMD, a muscle-targeted excision program for Duchenne muscular dystrophy. News items discuss preclinical data on dystrophin restoration and functional muscle improvement, preparations for investigational new drug (IND) submissions, and plans for Phase 1/2 clinical studies in DMD patients with mutations in exons 45–55 of the dystrophin gene.
Investors can also find updates on partnered in vivo programs, such as ECUR-506 for neonatal onset OTC deficiency developed by iECURE using a licensed ARCUS nuclease, along with regulatory milestones like RMAT designation. Additional coverage includes progress in non-core ex vivo programs such as azer-cel, an allogeneic CAR T therapy being advanced by partners for lymphoma and autoimmune diseases.
Financial and corporate news, including quarterly results, equity offerings, and strategic priorities, round out the DTIL news stream. For those tracking gene editing, hepatitis B, DMD, and ARCUS-based therapies, this page provides an organized view of Precision BioSciences’ latest disclosures and clinical developments over time.
Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, has announced that it will release its second quarter 2024 financial results and provide a business update on August 1, 2024. The company utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies. This upcoming report will offer investors and analysts insights into Precision BioSciences' financial performance and operational progress for the quarter ending June 30, 2024.
Precision BioSciences, a leader in gene editing utilizing its proprietary ARCUS® platform, has announced its participation in the JonesTrading Healthcare Seaside Summit from July 14-16, 2024, in San Diego, California. The company, trading under the Nasdaq ticker DTIL, will present on Monday, July 15, 2024, at 9:30 AM PT. The presentation will be accessible via live webcast on Precision BioSciences' website, specifically in the Investors section under Events & Presentations. An archived replay will be available for 30 days post-event.
Precision BioSciences (Nasdaq: DTIL), a gene editing company, announced its inclusion in the Russell Microcap® Index. This follows the 2024 Russell indexes annual reconstitution effective June 28, 2024. The inclusion reflects Precision's progress in advancing its PBGENE-HBV and PBGENE-PMM gene editing programs towards clinical trials in 2024 and 2025. CEO Michael Amoroso highlighted that the inclusion would enhance visibility among global investors. The Russell Microcap® Index captures the 4,000 largest US stocks by market capitalization and serves as a benchmark for $10.5 trillion in assets.
Precision BioSciences (Nasdaq: DTIL) announced the presentation of its PBGENE-PMM program at the UMDF Mitochondrial Medicine 2024 Conference in Cleveland, Ohio. The program targets m.3243 mitochondrial disease using the ARCUS® platform for gene editing. PBGENE-PMM aims to eliminate mutant mitochondrial DNA while preserving normal DNA, improving mitochondrial function. The presentation by Dr. Wendy Shoop demonstrated ARCUS' precision in localizing to mitochondria and avoiding off-target nuclear genome edits. The company is working towards filing an IND or CTA in 2025.
Precision BioSciences has announced the appointment of Dr. Mark Sulkowski and Dr. Jordan Feld to its Hepatitis Scientific Advisory Board. Both are esteemed clinicians in the field of hepatitis. This move aims to bolster the company's expertise as it prepares to submit IND and/or CTA applications for its PBGENE-HBV program in the second half of 2024. The additions aim to enhance the development and potential approval of PBGENE-HBV, which utilizes Precision’s proprietary ARCUS gene-editing platform. The advisory board will now include three key experts: Dr. Sulkowski, Dr. Feld, and Dr. Raymond Schinazi.
Precision BioSciences (Nasdaq: DTIL) has announced promising preclinical safety data for its PBGENE-HBV candidate at the European Association for the Study of the Liver Congress. The data demonstrate that PBGENE-HBV can specifically target and cut HBV DNA without affecting the human genome, showing high specificity and no detectable off-target editing. Additionally, non-human primate studies indicated that PBGENE-HBV is well-tolerated, even with multiple administrations. This supports the candidate's potential as a curative treatment for chronic hepatitis B. Precision BioSciences aims to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-HBV in 2024.
Precision BioSciences (Nasdaq: DTIL) will participate in two significant investor conferences in June 2024. The company, known for its ARCUS® gene editing platform, will be present at the Jefferies Global Healthcare Conference on June 5, 2024, from 1:30 pm to 1:55 pm ET, and at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, from 10:00 am to 10:35 am ET. Both events will feature fireside chats with management. Live webcasts will be available on Precision BioSciences' website, with replays accessible for 30 days post-event.
On May 13, 2024, Precision BioSciences announced the grant of inducement awards to new employees, approved by the Compensation Committee of its Board of Directors. These awards, given under the 2021 Employment Inducement Incentive Award Plan, include stock options for 18,511 shares and 17,124 restricted stock units (RSUs). Each stock option has an exercise price of $11.50 per share, a 10-year term, and vests over four years. The RSUs vest annually over three years. These awards are intended to attract new talent to the company.
Precision BioSciences, Inc. (Nasdaq: DTIL) reported their first quarter 2024 financial results and provided a business update. The company is focused on advancing its wholly owned gene editing programs for Hepatitis B virus and primary mitochondrial myopathy. Precision also exercised the option to return three preclinical programs for internal development or with partners. They monetized CAR T assets through licensing deals and completed a $40 million common stock offering to extend cash runway into H2 2026. Financially, Precision had $137.8 million in cash and cash equivalents as of March 31, 2024, with total revenues of $17.6 million for the quarter. Research and development expenses increased to $13.3 million, while general and administrative expenses decreased to $8.4 million. Net income from continuing operations was $8.6 million for the quarter.
Precision BioSciences, Inc. announced a private placement where the company will issue and sell 25,000 shares of common stock to its senior leadership team, including the CEO, at a price of $12.00 per share, totaling $300,000. The Private Placement is set to close on May 8, 2024, with the net proceeds intended for research and development initiatives.